{"database": "lobbying", "table": "lobbying_activities", "rows": [[3490114, "3e3115b4-c01e-4af1-be13-e99d752844b8", "Q4", "DLA PIPER LLP (US)", 76855, "AVALYN PHARMA INC.", 2025, "fourth_quarter", "MED", "Issues related to lung disease and rare disease.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2026-01-16T15:09:39-05:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3490114"], "units": {}, "query_ms": 13.966870959848166, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}